N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-lectin conjugates were investigated for potential use as targeted oral drug carriers for treatment of inflammatory conditions such as colitis. Wheat germ agglutinin (WGA)-HPMA copolymer and peanut agglutinin (PNA)-HPMA copolymer and fluorescein isothiocyanate (FITC)-labeled WGA- and PNA-HPMA copolymer conjugates were synthesized. Conjugate dissociation constants (Kd) for lectin-carbohydrate binding determined by frontal affinity chromatography indicated that no activity reduction of the lectins occurred during the synthesis of these conjugates. Kd values measured were in good agreement with literature findings for similar lectin-carbohydrate interactions, on the order of 10−5 M−1. Biorecognition of these conjugates by healthy rat intestinal tissue resulted in differential HPMA copolymer-lectin conjugate binding patterns in the same tissue. HPMA copolymer-WGA conjugate showed strong binding in the healthy rat intestinal tissues, while the HPMA copolymer-PNA conjugate showed minimal, but specific binding. This differential binding suggests that site-specific drug delivery via specific lectin recognition may be feasible for treatment of colon inflammation or cancer.